These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

320 related items for PubMed ID: 31173242

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. The narrow-spectrum HDAC inhibitor entinostat enhances NKG2D expression without NK cell toxicity, leading to enhanced recognition of cancer cells.
    Zhu S, Denman CJ, Cobanoglu ZS, Kiany S, Lau CC, Gottschalk SM, Hughes DP, Kleinerman ES, Lee DA.
    Pharm Res; 2015 Mar; 32(3):779-92. PubMed ID: 24203492
    [Abstract] [Full Text] [Related]

  • 5. Enhanced interaction between natural killer cells and lung cancer cells: involvement in gefitinib-mediated immunoregulation.
    He S, Yin T, Li D, Gao X, Wan Y, Ma X, Ye T, Guo F, Sun J, Lin Z, Wang Y.
    J Transl Med; 2013 Aug 12; 11():186. PubMed ID: 23937717
    [Abstract] [Full Text] [Related]

  • 6. Antibody targeting tumor-derived soluble NKG2D ligand sMIC reprograms NK cell homeostatic survival and function and enhances melanoma response to PDL1 blockade therapy.
    Basher F, Dhar P, Wang X, Wainwright DA, Zhang B, Sosman J, Ji Z, Wu JD.
    J Hematol Oncol; 2020 Jun 09; 13(1):74. PubMed ID: 32517713
    [Abstract] [Full Text] [Related]

  • 7. Taxanes enhance trastuzumab-mediated ADCC on tumor cells through NKG2D-mediated NK cell recognition.
    Di Modica M, Sfondrini L, Regondi V, Varchetta S, Oliviero B, Mariani G, Bianchi GV, Generali D, Balsari A, Triulzi T, Tagliabue E.
    Oncotarget; 2016 Jan 05; 7(1):255-65. PubMed ID: 26595802
    [Abstract] [Full Text] [Related]

  • 8. Cervical cancer cell lines expressing NKG2D-ligands are able to down-modulate the NKG2D receptor on NKL cells with functional implications.
    Jimenez-Perez MI, Jave-Suarez LF, Ortiz-Lazareno PC, Bravo-Cuellar A, Gonzalez-Ramella O, Aguilar-Lemarroy A, Hernandez-Flores G, Pereira-Suarez AL, Daneri-Navarro A, del Toro-Arreola S.
    BMC Immunol; 2012 Feb 08; 13():7. PubMed ID: 22316211
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Upregulation of NKG2D ligands in acute lymphoblastic leukemia and non-Hodgkin lymphoma cells by romidepsin and enhanced in vitro and in vivo natural killer cell cytotoxicity.
    Satwani P, Bavishi S, Saha A, Zhao F, Ayello J, van de Ven C, Chu Y, Cairo MS.
    Cytotherapy; 2014 Oct 08; 16(10):1431-40. PubMed ID: 24856896
    [Abstract] [Full Text] [Related]

  • 12. Human NK cells are alerted to induction of p53 in cancer cells by upregulation of the NKG2D ligands ULBP1 and ULBP2.
    Textor S, Fiegler N, Arnold A, Porgador A, Hofmann TG, Cerwenka A.
    Cancer Res; 2011 Sep 15; 71(18):5998-6009. PubMed ID: 21764762
    [Abstract] [Full Text] [Related]

  • 13. Inhibition of MMP activity can restore NKG2D ligand expression in gastric cancer, leading to improved NK cell susceptibility.
    Shiraishi K, Mimura K, Kua LF, Koh V, Siang LK, Nakajima S, Fujii H, Shabbir A, Yong WP, So J, Takenoshita S, Kono K.
    J Gastroenterol; 2016 Dec 15; 51(12):1101-1111. PubMed ID: 27002316
    [Abstract] [Full Text] [Related]

  • 14. Resveratrol sensitized leukemia stem cell-like KG-1a cells to cytokine-induced killer cells-mediated cytolysis through NKG2D ligands and TRAIL receptors.
    Hu L, Cao D, Li Y, He Y, Guo K.
    Cancer Biol Ther; 2012 May 15; 13(7):516-26. PubMed ID: 22406996
    [Abstract] [Full Text] [Related]

  • 15. Inhibition of IL-6-JAK/Stat3 signaling in castration-resistant prostate cancer cells enhances the NK cell-mediated cytotoxicity via alteration of PD-L1/NKG2D ligand levels.
    Xu L, Chen X, Shen M, Yang DR, Fang L, Weng G, Tsai Y, Keng PC, Chen Y, Lee SO.
    Mol Oncol; 2018 Mar 15; 12(3):269-286. PubMed ID: 28865178
    [Abstract] [Full Text] [Related]

  • 16. Functional Characterisation and Analysis of the Soluble NKG2D Ligand Repertoire Detected in Umbilical Cord Blood Plasma.
    Cox ST, Danby R, Hernandez D, Laza-Briviesca R, Pearson H, Madrigal JA, Saudemont A.
    Front Immunol; 2018 Mar 15; 9():1282. PubMed ID: 29963042
    [Abstract] [Full Text] [Related]

  • 17. Upregulation of programmed cell death ligand 1 promotes resistance response in non-small-cell lung cancer patients treated with neo-adjuvant chemotherapy.
    Zhang P, Ma Y, Lv C, Huang M, Li M, Dong B, Liu X, An G, Zhang W, Zhang J, Zhang L, Zhang S, Yang Y.
    Cancer Sci; 2016 Nov 15; 107(11):1563-1571. PubMed ID: 27581532
    [Abstract] [Full Text] [Related]

  • 18. Cisplatin enhances NK cells immunotherapy efficacy to suppress HCC progression via altering the androgen receptor (AR)-ULBP2 signals.
    Shi L, Lin H, Li G, Sun Y, Shen J, Xu J, Lin C, Yeh S, Cai X, Chang C.
    Cancer Lett; 2016 Apr 01; 373(1):45-56. PubMed ID: 26805759
    [Abstract] [Full Text] [Related]

  • 19. Combined inhibition of JAK1,2/Stat3‑PD‑L1 signaling pathway suppresses the immune escape of castration‑resistant prostate cancer to NK cells in hypoxia.
    Xu LJ, Ma Q, Zhu J, Li J, Xue BX, Gao J, Sun CY, Zang YC, Zhou YB, Yang DR, Shan YX.
    Mol Med Rep; 2018 Jun 01; 17(6):8111-8120. PubMed ID: 29693186
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.